- freely available
Developments and Challenges for mAb-Based Therapeutics
AbstractThe continuous increase in the number of approved monoclonal antibody (mAb)-based therapy suggests that mAbs, and their derivatives, will continue to be the focus of the biotherapeutics industry for years to come. Although vast improvements in our capability to manufacture, characterize, and stabilize mAbs have been achieved, there are still challenges to be overcome. These include analytical and stabilization approaches associated with the development of high concentration mAb formulations. In addition, several mAb-based modalities are under development, including antibody drug conjugates (ADCs), fusion proteins, and bispecific antibodies (bsAbs), all designed to overcome the limitations encountered with mAb therapy. The current status of their development, with emphasis on manufacturing challenges as well as preliminary clinical results, will be reviewed.
Share & Cite This Article
Goswami, S.; Wang, W.; Arakawa, T.; Ohtake, S. Developments and Challenges for mAb-Based Therapeutics. Antibodies 2013, 2, 452-500.View more citation formats
Goswami S, Wang W, Arakawa T, Ohtake S. Developments and Challenges for mAb-Based Therapeutics. Antibodies. 2013; 2(3):452-500.Chicago/Turabian Style
Goswami, Sumit; Wang, Wei; Arakawa, Tsutomu; Ohtake, Satoshi. 2013. "Developments and Challenges for mAb-Based Therapeutics." Antibodies 2, no. 3: 452-500.
Notes: Multiple requests from the same IP address are counted as one view.